Jerrold B Grossman

Director Jerrold B Grossman buys 6,400 ADMA shares at $7.91; stock down -64.6% from 52-week high of $22.37

Jerrold B Grossman, a director, purchased 6,400 shares at $7.91 on 2026-05-27, increasing his holdings to 520,284 shares. This occurs as ADMA trades at $7.93, representing a significant decline of -64.6% from the 52-week high of $22.37 and a 90-day decline of -49.1%. Grossman's cross-ticker track record shows mixed results: his 3 prior buys averaged -1.1% returns over 90 days with a 0.00% win rate, while his same-ticker history at ADMA includes two recent purchases (2026-05-12 and 2026-05-11) that each returned -1.1% over 90 days. The company's fundamentals remain solid with revenue of $114,493,000.00, net income of $45,328,000.00, a P/E of 11.17, and annual revenue growth of +19.6%, but the substantial stock price decline raises questions about market confidence despite operational performance.

ADMA Biologics director Grossman buys 12,500 shares in 3rd open-market purchase at ADMA in under 3 years, adding to position near 52-week lows

Director Jerrold B. Grossman made his third open-market purchase of ADMA Biologics shares in the 36-month window, acquiring 12,500 shares and expanding his direct stake from roughly 501,000 to nearly 514,000 shares. The stock is trading sharply below its 52-week high and near its 52-week low, having declined substantially over both the past month and the past three months — meaning Grossman is stepping into meaningful recent weakness. ADMA Biologics is a profitable company with growing annual revenue, and its valuation appears modest relative to its earnings, which provides some fundamental backdrop for a director's open-market commitment. Grossman's same-ticker track record shows mixed results: his one evaluated prior buy at this stock was well-timed at both the 30-day and 90-day marks, while his one evaluated prior sell was poorly timed — the stock rose significantly in the months that followed. Taken together, the director is a repeat open-market buyer at this company whose single evaluated prior buy produced a positive outcome, though his selling record at this ticker has been less accurate, making the overall track record mixed.

Director Jerrold B Grossman purchases 12,500 ADMA shares at $8.01 as stock trades well below 52-week highs amid broad decline.

Jerrold B Grossman, a director of ADMA Biologics, purchased a substantial position of 12,500 shares at prices near the 52-week low, following a sharp stock decline. This marks his second open-market purchase in the past three years, adding to prior buying activity. The timing is contrarian—he is buying into weakness at a point where the stock has fallen sharply from its 52-week high. However, his track record offers a cautionary note: his most recent prior sale in this stock was poorly timed, as the stock rose significantly afterward, suggesting limited accuracy in read ng the company's trajectory. ADMA remains a profitable company with growing revenue, yet the director's purchase arrives during an extended pullback, buying shares at depressed levels rather than at prior peaks.

Director Grossman sells 136.9K ADMA shares at $17.27, reducing stake to 467.3K shares; stock up 41% in 30 days.

Director Jerrold B Grossman sold 136,861 shares at $17.27, representing a 22.7% reduction in his stake from 604,166 to 467,305 shares. The sale occurred as ADMA's stock has appreciated significantly—up 41.0% in the prior 30 days and 81.3% over 90 days—though the price remains 5.9% below its 52-week high of $18.40. Historically, Grossman's prior transaction at this ticker (a buy on 2023-08-30) achieved a 90-day return of +0.3%, marking one of one well-timed buys at ADMA. The company shows strong near-term revenue growth (+67.6% annual) and a recent profitable quarter ($32.1M net income), though it carried negative full-year net income historically. The elevated P/E of 115.40 and current momentum warrant focus on whether the stock's sharp gains represent sustainable value or timing-driven appreciation.